文献速递心境障碍焦虑、强迫与应激相关障碍

生长激素释放激素受体拮抗剂MIA-602在情绪障碍小鼠中的效应:PTSD的潜在治疗

Effects of growth hormone-releasing hormone receptor antagonist MIA-602 in mice with emotional disorders: a potential treatment for PTSD.
PubMed 文献 · Mol Psychiatry · 2021-07-30

该研究在成年小鼠中评估了新型生长激素释放激素(GHRH)拮抗剂MIA-602对焦虑和抑郁样行为的作用。皮下治疗4周后,MIA-602表现出抗炎和抗氧化效应,并诱导抗焦虑和抗抑郁样行为,其机制可能与海马和前额叶皮层中Nrf2和BDNF信号通路上调有关。结果提示GHRH类似物值得在包括PTSD在内的情绪障碍中开展临床试验。

要点

  • MIA-602皮下治疗4周在小鼠中诱导抗焦虑和抗抑郁样行为。
  • MIA-602在离体和在体模型中表现出抗炎和抗氧化效应。
  • 其保护作用可能与海马和前额叶皮层Nrf2及BDNF信号上调有关。

核心结论

  • MIA-602可能通过上调海马和前额叶皮层Nrf2与BDNF信号通路,改善炎症和氧化状态并促进突触发生,从而产生抗焦虑和抗抑郁样效应。
  • 结果提示GHRH类似物值得在包括PTSD在内的情绪障碍中开展临床尝试。

研究设计与样本

  • 在成年小鼠中开展的在体和离体实验研究,评估MIA-602对情绪障碍相关行为及脑内通路的作用。
  • 小鼠接受MIA-602皮下治疗4周。

主要发现

  • MIA-602在离体和在体实验模型中表现出抗炎和抗氧化效应。
  • MIA-602皮下治疗4周诱导小鼠出现抗焦虑和抗抑郁样行为。
  • MIA-602对炎症和氧化状态及突触发生的有益效应可能与海马和前额叶皮层中Nrf2和BDNF信号通路的增加有关。

临床怎么用

  • 目前仅为动物实验证据,不支持直接用于临床决策。
  • 提示GHRH拮抗剂类化合物可作为情绪障碍包括PTSD的潜在候选药物进行后续临床研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anxiety and depression have been suggested to increase the risk for post-traumatic stress disorders (PTSD). A link between all these mental illnesses, inflammation and oxidative stress is also well established. Recent behavior studies by our group clearly demonstrate a powerful anxiolytic and antidepressant-like effects of a novel growth hormone releasing hormone (GHRH) antagonist of MIAMI class, MIA-690, probably related to modulatory effects on the inflammatory and oxidative status. In the present work we investigated the potential beneficial effects of MIA-602, another recently developed GHRH antagonist, in mood disorders, as anxiety and depression, and the possible brain pathways involved in its protective activity, in adult mice. MIA-602 exhibited antinflammatory and antioxidant effects in ex vivo and in vivo experimental models, inducing anxiolytic and antidepressant-like behavior in mice subcutaneously treated for 4 weeks. The beneficial effect of MIA-602 on inflammatory and oxidative status and synaptogenesis resulting in anxiolytic and antidepressant-like effects could be related by increases of nuclear factor erythroid 2-related factor 2 (Nrf2) and of brain-derived neurotrophic factor (BDNF) signaling pathways in the hippocampus and prefrontal cortex. These results strongly suggest that GHRH analogs should be tried clinically for the treatment of mood disorders including PTSD.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Recinella L, Chiavaroli A, Orlando G, et al. Effects of growth hormone-releasing hormone receptor antagonist MIA-602 in mice with emotional disorders: a potential treatment for PTSD. Mol Psychiatry. 2021. PMID: 34331008. doi:10.1038/s41380-021-01228-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。